Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine.
Giménez E, Albert E, Zulaica J, Torres I, Rusu L, Moreno AR, Burgos JS, Peiró S, Salas D, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R, Navarro D; Valencian Vaccine Research Program (ProVaVac) Study Group. Giménez E, et al. Clin Infect Dis. 2022 Aug 24;75(1):e865-e868. doi: 10.1093/cid/ciac223. Clin Infect Dis. 2022. PMID: 35314856 Free PMC article.
Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents.
Albert E, Burgos JS, Peiró S, Salas D, Vanaclocha H, Giménez E, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Navarro D; Valencian Vaccine Research Programme (ProVaVac) Study Group. Albert E, et al. Clin Microbiol Infect. 2022 Feb;28(2):279-284. doi: 10.1016/j.cmi.2021.09.031. Epub 2021 Oct 5. Clin Microbiol Infect. 2022. PMID: 34619398 Free PMC article.
SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine.
Giménez E, Albert E, Burgos JS, Peiró S, Salas D, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F; Valencian vaccine research program (ProVaVac) study group. Giménez E, et al. J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.02.035. Epub 2022 Mar 2. J Infect. 2022. PMID: 35245583 Free PMC article.
SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gascó-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, Martínez-Serrano M, Ortíz-Rambla J, Buj H, Hernández N, Peiró S, Salas D, Limón R, Vanaclocha H, Sánchez-Payá J, Díez-Domingo J, Comas I, González-Candelas F, Navarro D; Valencian vaccine research program (ProVaVac) study group. Torres I, et al. J Med Virol. 2022 Aug;94(8):3776-3782. doi: 10.1002/jmv.27799. Epub 2022 Apr 27. J Med Virol. 2022. PMID: 35445415 Free PMC article.
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
Torres I, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Burgos JS, Peiró S, Limón R, Vanaclocha H, Rodado C, Botija P, Sifre A, Tur B, Lozano RA, Orosa I, Vicente-Ruiz M, Carrión RJ, Clari MÁ, Sánchez-Payá J, Díez-Domingo J, Comas I, González-Candelas F, Geller R, Navarro D; Valencian vaccine research program (ProVaVac) study group. Torres I, et al. J Med Virol. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. Epub 2022 May 25. J Med Virol. 2022. PMID: 35585782 Free PMC article.
The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).
Chico-Sánchez P, Gras-Valentí P, Algado-Sellés N, Jiménez-Sepúlveda N, Vanaclocha H, Peiró S, Burgos JS, Berenguer A, Navarro D, Sánchez-Payá J; Valencian vaccine research program (ProVaVac) study group. Chico-Sánchez P, et al. Prev Med. 2022 Oct;163:107237. doi: 10.1016/j.ypmed.2022.107237. Epub 2022 Aug 31. Prev Med. 2022. PMID: 36057393 Free PMC article.
Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.
Sánchez-Saez F, Peiró S, Cuenca L, Vanaclocha H, Limón R, Salas D, Burgos JS, Sánchez-Payá J, Meneu R, Díez J, García-Sempere A, Navarro IH, Rodríguez-Bernal C, Sanfélix-Gimeno G, Navarro D; Valencian vaccine research program (ProVaVac) study group. Sánchez-Saez F, et al. Vaccine. 2022 Sep 29;40(41):5942-5949. doi: 10.1016/j.vaccine.2022.08.028. Epub 2022 Aug 29. Vaccine. 2022. PMID: 36068110 Free PMC article.
Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant.
Camacho J, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Torres I, Rusu L, Burgos JS, Peiró S, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R, Navarro D; Valencian Vaccine Research Program (ProVaVac) study group. Camacho J, et al. J Med Virol. 2023 Jan;95(1):e28284. doi: 10.1002/jmv.28284. Epub 2022 Nov 11. J Med Virol. 2023. PMID: 36333837 Free PMC article.
The COVID-GRAM Tool for Patients Hospitalized With COVID-19 in Europe.
Moreno-Pérez Ó, Andrés M, León-Ramirez JM, Sánchez-Payá J, Boix V, Gil J, Merino E. Moreno-Pérez Ó, et al. JAMA Intern Med. 2021 Jul 1;181(7):1000-1001. doi: 10.1001/jamainternmed.2021.0491. JAMA Intern Med. 2021. PMID: 33818609 Free PMC article.
216 results